AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02979561 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: all patients continue to receive unfractionated heparin intravenously and at the same time (from the date of randomization) start warfarin, accompanied by regular measurement of the INR every day or every other day. As soon as INR reaches the range of 2.0 to 3.0, the administration of the unfractionated heparin should be discontinued. Further measurements of INR should be performed once a month during outpatient visits. The patient continues to receive warfarin under the control of the INR till the end of the treatment period. The treatment period starts on the day of randomization and lasts for 6 months.
Study NCT03785444 — intervention group
Intervention type: OTHER
Intervention: WHODAS 2.0
Description: WHO Disability Score
Study NCT03785444 — intervention group
Intervention type: OTHER
Intervention: EQ5D
Description: Health related quality of life measured with European Quality of Life 5 Dimensions 5 Level
Study NCT03785444 — intervention group
Intervention type: OTHER
Intervention: IADL
Description: The Lawton Instrumental Activities of Daily Living
Study NCT03785444 — intervention group
Intervention type: OTHER
Intervention: Barthel-Score
Description: Barthel Score of the patient
Study NCT03785444 — intervention group
Intervention type: OTHER
Intervention: SF-36
Description: Short Form Health 36
Study NCT03785444 — intervention group
Intervention type: OTHER
Intervention: MoCA Blind
Description: Montreal Cognitive Assessment
Study NCT01390038 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Simpliciti™ Shoulder System
Description: Total shoulder arthroplasty system
Study NCT03898388 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Concentrate treatment
Description: Correlate patient outcomes 6 months after receiving the Regenexx SD treatment with measurements of synovial fluid collected before treatment
Study NCT01369446 — intervention group
Intervention type: DEVICE
Intervention: Eeva System Study
Description: The Eeva System will image embryos through cleavage and/or blastocyst stage.
Study NCT00383708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lanreotide (Autogel formulation)
Description: 120 mg administered via deep subcutaneous injection every 28 days over 28 weeks.
Study NCT00383708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegvisomant
Description: Administered at 40 to 120 mg per week via subcutaneous injection once or twice a week over 28 weeks.
Study NCT04348786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: Doxycylcine 100 mg bid ,esomprazole 20 bid,Bismuth subsalicylate 262 tab.2 tab q.i.d,Tinadizole 500 bid
Study NCT04348786 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levofloxacin 500mg
Description: Levofloxacin 500 mg qd, amoxicillin 500 2cab bid,Tinadizole 500 bid, esomprazole 20 bid
Study NCT01843634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ODSH
Study NCT02396693 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIPPV
Description: Ventilation with nasal intermittent positive pressure - Newborns randomized to this group underwent NIPPV, the respirators in TIME mode, set with the following settings : 5-6 centimeters of water (cmH2O) pressure positive end expiratory (PEEP); Flow rate of 6-8 liters per minute (L / min); PIP(positive inspiratory pressure) \< 15 centimeters of water (cm H2O) ; respiratory frequency backup (FR) \< 16 bpm; inspiratory time (IT) - 0.30 to 0.33 seconds (adjustable time constant according to the weight and baseline disease)
Study NCT02396693 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Bubble NCPAP
Description: Bubble NCPAP - Newborns randomized to this group bubble NCPAP, adjusted with the following settings: pressure positive end expiratory (PEEP) 5-6 centimeters of water (cm H2O) and Flow 6-8 liters per minute (L / min), provided through oxygen sources and compressed air (15 liters per minute - L / min), which passes through a heated humidifier through a breathing circuit that goes to the newborn, and from him, for a plastic container (250 milliliters (ml) capacity and 14 centimeters) containing sterile distilled water, which is the bubble.
Study NCT02396693 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Ventilator NCPAP
Description: Ventilator NCPAP - Newborns randomized to this group ventilator NCPAP, of respirators in TIME mode set with the following settings: pressure positive end expiratory (PEEP) 5-6 centimeters of water (cm H2O) and Flow 6-8 liters per minute (L / min).
Study NCT03577951 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: high position space group
Description: The left and right Trocar meet at the level of the sternum angle and begin to establish the operating space.
Study NCT03577951 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: low position space group
Description: The left and right Trocar meet under the sternum angle and begin to establish the operating space.
Study NCT01841489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: 1600 mg GS-9973 (Formulation 1)
Study NCT01841489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: 1600 mg GS-9973 (Formulation 1) plus 20 mg omeprazole
Study NCT01841489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C
Description: 1600 mg GS-9973 (Formulation 1) plus 40 mg famotidine
Study NCT01841489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment D
Description: 1600 mg GS-9973 (Formulation 2)
Study NCT01841489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment E
Description: 1600 mg GS-9973 (Formulation 2) plus 20 mg omeprazole
Study NCT01841489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment F
Description: 1600 mg GS-9973 (Formulation 2) plus 40 mg famotidine
Study NCT01841489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment G
Description: 1600 mg GS-9973 (Reference formulation)
Study NCT01841489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment H
Description: 1600 mg GS-9973 (Formulation 1 or Formulation 2, based on results from Part A)
Study NCT01841489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment I
Description: An alternate dose of the chosen formulation from Part A up to 1200 mg administered twice-daily
Study NCT01841489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment J
Description: An alternate dose of the chosen formulation from Part A up to 1200 mg administered twice-daily
Study NCT00368472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perampanel
Description: Perampanel 2 mg to 12 mg, once daily during the OLE study
Study NCT01570452 — intervention group
Intervention type: PROCEDURE
Intervention: colonic or colorectal resection
Description: standard laparotomic resection of colon-rectum including right hemicolectomy, left hemicolectomy, sigmoidectomy, anterior resection
Study NCT03615989 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Resistance and Plyometric Exercise
Description: A single resistance and plyometric exercise bout per trial.
Study NCT03615989 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance and Plyometric Exercise
Description: A single resistance and plyometric exercise bout per trial.
Study NCT03615989 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Carbohydrate (Maltodextrin powder mixed with water)
Description: 50 grams immediately after exercise bout. 50 grams 1 hour after exercise bout.
Study NCT03615989 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Skim Milk
Description: 500 ml immediately after exercise bout. 500 ml 1 hour after exercise bout.
Study NCT02574481 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ELUVIA (Stent Implantation)
Description: Drug-eluting self-expanding stent implantation during the index procedure.
Study NCT02554136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP0816
Study NCT02574481 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Zilver PTX (Stent Implantation)
Description: Drug-eluting self-expanding stent implantation during the index procedure.
Study NCT00796003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-30979754 15 mg/m2
Description: JNJ-30979754 (decitabine) 15 mg/m2 will be administered once daily by 1-hour intravenous infusion from Day 1 to 5 of 4-Week (28-day) Cycle 1.
Study NCT02554136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP0918 + HGP0816
Study NCT03682224 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal Bupivacaine
Description: Liposomal Bupivacaine 1.3% (Exparel), 20 ml vial for injection, administered subcutaneously at port site
Study NCT03682224 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine-Epinephrine
Description: Bupivacaine-Epinephrine 0.25%, 1:200,000 (Marcaine with epinephrine), administered subcutaneously at port site
Study NCT02416414 — intervention group
Intervention type: DEVICE
Intervention: QuantiFERON Monitor Assay
Description: Assay to measure cell-mediated immune function using QuantiFERON Monitor assay.
Study NCT02416414 — intervention group
Intervention type: DEVICE
Intervention: Existing methodology
Description: Assay to measure cell-mediated immune function using existing methodology.
Study NCT00227110 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: 30 mg/d for 8 weeks and titrated to 45 mg/d until completing 6 months of treatment.
Study NCT00227110 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is given to match pioglitazone.
Study NCT00796003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-30979754 20 mg/m2
Description: Phase I: JNJ-30979754 (decitabine) 20 mg/m2 will be administered once daily by 1-hour intravenous infusion from Day 1 to 5 of 4-Week (28-day) Cycle 1. Phase II: JNJ-30979754 (decitabine) 20 mg/m2 will be administered once daily by 1-hour intravenous infusion from Day 1 to 5 of 4-Week (28-day) cycles until the decitabine was expected to be effective in participants.
Study NCT02045082 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Corneal sampling
Description: Slit lamp corneal sampling with a Swab
Study NCT01761370 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: AHA diet plus exercise with BIB placement
Description: AHA diet plus exercise with BIB placement for 6 months
Study NCT01761370 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: AHA diet plus exercise with sham BIB placement
Description: AHA diet plus exercise with sham BIB placement
Study NCT01830218 — intervention group
Intervention type: PROCEDURE
Intervention: Obstetric anesthesia and analgesia
Description: All anesthesia procedures during labor: labor analgesia, anesthesia for Cesarean section, anesthesia for procedures in third stage of labor
Study NCT00946686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leflunomide 20 mg Tablets (Geneva Pharmaceutical)
Study NCT00946686 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arava 20 mg Tablets (Aventis Pharmaceutical, Inc.)
Study NCT03557424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyglucosamine Glucomannan normal dose (Verum)
Description: Patients received Verum three times a day for 65 days. The patients had to dissolve the powder included in one sachet in 250 ml water and drink the solution 15 minutes before each meal. It was recorded whether the patients changed their Lifestyle (their dietary habits and doing sports) during the study.
Study NCT03557424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyglucosamine Glucomannan high dose (Verum)
Description: Patients received Verum 2 three times a day for 65 days. The patients had to dissolve the powder included in one sachet in 250 ml water and drink the solution 15 minutes before each meal. It was recorded whether the patients changed their Lifestyle (their dietary habits and doing sports) during the study.
Study NCT03557424 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: Placebo
Description: Patients received Placebo three times a day for 65 days. The patients had to dissolve the powder included in one sachet in 250 ml water and drink the solution 15 minutes before each meal. It was recorded whether the patients changed their Lifestyle (their dietary habits and doing sports) during the study.
Study NCT03576482 — intervention group
Intervention type: OTHER
Intervention: Transport on foot
Description: Patients go to operating room walking with their families and with their normal clothes
Study NCT04488835 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electromagnetic field therapy and transcutaneous electrical nerve stimulation
Description: Both groups received conventional physical therapy treatment protocol. Moreover, group (A) has an additional TENS application and group (B) had PEMFS application. TENS and the PEMFT were applied once daily, three times per week for 20 minutes for each session. Assessment performed pre and post intervention using visual analogue scale (VAS) and estimation of the carbamazepine intake (CMI).
Study NCT02023918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegvisomant
Description: Pegvisomant 20 mg subcutaneously Qday will be administered by the study subject for 28 days during this study.
Study NCT02852720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levobupivacaine
Description: After the block procedure, 2 ml blood samples will be taken in defined times to determine the plasma blood levels of levobupivacaine.
Study NCT02852720 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia
Description: Spinal anesthesia in the L3-L4 or L4-L5 interspace with hyperbaric bupivacaine 0,75% 1,4 ml plus 20 ug fentanyl to achieve a bilateral anesthetic level of T4 determined by pinprick.
Study NCT02852720 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral vein canulation
Description: An intravenous (18-gauge) catheter will be placed under local anesthesia for co hydration and a second IV catheter for venous sampling
Study NCT02852720 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasonography
Description: TAP blocks will be performed using a ultrasound Sonosite M-Turbo US machine (Sonosite Inc, Washington) with an L38x 10-5 megahertz (MHz), 38-mm broadband linear array probe.
Study NCT02852720 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Holter
Description: A portable 12-lead Holter (NorthEast Monitoring®, Boston, USA) will record continuously the electrocardiogram (ECG) after the TAP block, for 24 hrs.
Study NCT01630967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: Standard dosing and schedule for administration of degarelix will be used. 240mg s.c. loading dose, 80mg s.c. monthly maintenance dose.
Study NCT02726048 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Simplus/Eson
Description: Released product Simplus and Eson masks
Study NCT04194515 — intervention group
Intervention type: DRUG
Intervention: YH1
Description: YH1 treatment for one month
Study NCT04194515 — intervention group
Intervention type: DRUG
Intervention: metformin
Description: metformin treatment for one month
Study NCT02518516 — intervention group
Intervention type: DRUG
Intervention: Rosuvastatin (≥10 mg)
Description: Current cumulative exposure to high dose rosuvastatin (ATC C10AA07) will be defined as a prescription for ≥10 mg of rosuvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-365 days, or 366-730 days).~Past exposure to high dose rosuvastatin (ATC C10AA07) will be defined as a prescription for ≥10 mg of rosuvastatin dispensed >120 days of the index date (i.e. no exposure within 120 days of the index date).
Study NCT02518516 — intervention group
Intervention type: DRUG
Intervention: Atorvastatin (≥20 mg)
Description: Current cumulative exposure to high dose atorvastatin (ATC C10AA05) will be defined as a prescription for ≥20 mg of atorvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-365 days, or 366-730 days).~Past exposure to high dose atorvastatin (ATC C10AA05) will be defined as a prescription for ≥20 mg of atorvastatin dispensed >120 days prior to the index date (i.e. no exposure within 120 days of the index date).
Study NCT02518516 — intervention group
Intervention type: DRUG
Intervention: Simvastatin (≥40 mg)
Description: Current cumulative exposure to high dose simvastatin (ATC C10AA01) will be defined as a prescription for ≥40 mg simvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-365 days, or 366-730 days).~Past exposure to high dose simvastatin (ATC C10AA01) will be defined as a prescription for ≥40 mg simvastatin dispensed >120 days prior to the index date (i.e. no exposure within 120 days of the index date).
Study NCT02518516 — intervention group
Intervention type: DRUG
Intervention: Fluvastatin
Description: Current cumulative exposure to fluvastatin (ATC C10AA04) will be defined as a prescription for any dose of fluvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-365 days, or 366-730 days).~Past exposure to fluvastatin (ATC C10AA04) will be defined as a prescription for any dose of fluvastatin dispensed >120 days prior to the index date (i.e. no exposure within 120 days of the index date).
Study NCT02518516 — intervention group
Intervention type: DRUG
Intervention: Pravastatin
Description: Current cumulative exposure to pravastatin (ATC C10AA03) will be defined as a prescription for any dose of pravastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-365 days, or 366-730 days).~Past exposure to pravastatin will be defined as a prescription for any dose of pravastatin (ATC C10AA03) dispensed >120 days prior to the index date (i.e. no exposure within 120 days of the index date).
Study NCT02518516 — intervention group
Intervention type: DRUG
Intervention: Lovastatin
Description: Current cumulative exposure to lovastatin (ATC C10AA02) will be defined as a prescription for any dose of lovastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-365 days, or 366-730 days).~Past exposure to lovastatin will be defined as a prescription for any dose of lovastatin (ATC C10AA02) dispensed >120 days prior to the index date (i.e. no exposure within 120 days of the index date).
Study NCT02518516 — intervention group
Intervention type: DRUG
Intervention: Atorvastatin (<20mg)
Description: Current cumulative exposure to low dose atorvastatin (ATC C10AA05) will be defined as a prescription for \<20 mg of atorvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-365 days, or 366-730 days).~Past exposure to low dose atorvastatin (ATC C10AA05) will be defined as a prescription for \<20 mg of atorvastatin dispensed >120 days prior to the index date (i.e. no exposure within 120 days of the index date).
Study NCT02518516 — intervention group
Intervention type: DRUG
Intervention: Simvastatin (<40 mg)
Description: Current cumulative exposure to low dose simvastatin (ATC C10AA01) will be defined as a prescription for \<40 mg simvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-365 days, or 366-730 days).~Past exposure to low dose simvastatin (ATC C10AA01) will be defined as a prescription for \<40 mg simvastatin dispensed >120 days prior to the index date (i.e. no exposure within 120 days of the index date).
Study NCT02512653 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cupressus arizonica
Description: Four different concentrations of Cupressus arizonica allergen extract, positive control and negative control
Study NCT03321435 — intervention group
Intervention type: OTHER
Intervention: placenta previa patient
Description: women had placenta previa either major or minor degree
Study NCT01528995 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medtronic Interstim II-3058
Description: impulse generator
Study NCT01528995 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anal bulking injection
Description: Permacol injection:~four submucosal injections are administered at the 12, 3, 6 and 9 o'clock positions, above the level of the dentate line. The injection produces a bulge in the mucosa
Study NCT01769625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo/celecoxib 400 mg and cholecalciferol 400 IU/cholecalciferol 2,000 IU
Description: Take 1 capsule from each bottle (1 bottle containing either placebo/celecoxib and 1 bottle containing either cholecaliferol 400 IU/cholecaliferol 2,000 IU) for 30 days
Study NCT01769625 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo/celecoxib 400 mg and cholecalciferol 400 IU/cholecalciferol 2,000 IU
Description: Take 1 capsule from each bottle (1 bottle containing either placebo/celecoxib and 1 bottle containing either cholecaliferol 400 IU/cholecaliferol 2,000 IU) for 30 days
Study NCT03321435 — intervention group
Intervention type: OTHER
Intervention: normal women
Description: those women had not placenta previa
Study NCT00714961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel (SR25990)
Description: plus acetylsalicylic acid (ASA)
Study NCT00714961 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: plus acetylsalicylic acid (ASA)
Study NCT00107510 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pegfilgrastim
Study NCT00107510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Study NCT01769625 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo/celecoxib 400 mg and cholecalciferol 400 IU/cholecalciferol 2,000 IU
Description: Take 1 capsule from each bottle (1 bottle containing either placebo/celecoxib and 1 bottle containing either cholecaliferol 400 IU/cholecaliferol 2,000 IU) for 30 days